Improved Open-Access NMR for the Synthetic and Analytical Chemistry Laboratories

In this webinar Dr Mark Zell, Takeda Pharmaceuticals, and Dr. Anna Codina, Bruker BioSpin, will discuss the use of walk-up NMR instrumentation for pharmaceutical analysis in chemical and analytical R&D.

This webinar took place on
February
12th 2019

Register to download slides & media

Additional Documents

Overview

Nuclear magnetic resonance spectroscopy is a well-established technique popular for being quantitative by nature and giving unparalleled structural information of both solid and liquid samples. The drawback is that it is perceived as an expensive, difficult to use technique in the hands of few specialists. Due to advances in hardware, software, automation and workflow integration, this is no longer true.

NMR can nowadays be deployed to an open access environment in the chemistry and analytical laboratories. Reduced footprint NMR instruments are no longer installed in the basement, but in any floor, surrounded by other analytical instrumentation, fume cupboards and benches. Improved software makes data acquisition and processing of complex samples and experiments straightforward for even novice users.

What you will discover

In this webinar Dr. Mark Zell, Takeda Pharmaceuticals, and Dr. Anna Codina, Bruker BioSpin, will discuss the benefits of NMR as walk-up instrument in the pharmaceutical industry.

Key Points

Examples of NMR instrumentation in walk-up labs

Applications of the open access NMR for pharmaceutical chemical and analytical R&D

Benefits and return of investment of the open access NMR

Who should attend?

This webinar will be of interest to those looking to extend and improve their analytical capabilities, heads of medicinal chemistry, analytical and chemical R&D, laboratory managers and expert users of complementary technologies. It is especially dedicated for those seeking to understand the return of investment in NMR in emerging, growing markets.

Speakers

Mark Zell earned his Bachelor of Science degree from the University of Wisconsin – Milwaukee in 1995 and his Ph.D. in Analytical Chemistry from the University of Minnesota in 2000 under the direction of Professor Eric Munson. Following completion of his graduate studies, he worked briefly as a Research Scientist with Procter & Gamble Pharmaceuticals. In 2002, he joined Pfizer in Ann Arbor, Michigan working to develop the structure elucidation capabilities in the drug development organization. In 2007, he moved to the Pfizer facility in Groton, CT where he advanced to the role of Associate Research Fellow and NMR Team Leader in the Structure Elucidation Group, assisting in the advancement of the Pharmaceutical Sciences Open Access NMR lab, Quantitative NMR for routine use, reaction monitoring, and other NMR tools for project understanding. In 2017, he joined Takeda in Cambridge, Massachusetts as Associate Scientific Fellow and Structural Characterization Group Team Leader. His research interests involve the application of cutting-edge analytical instrumentation for structure elucidation and reaction monitoring. Dr. Zell is also a Courtesy Assistant Professor with the Department of Medicinal Chemistry at the University of Florida, College of Pharmacy, an appointment he has held since 2013. His responsibilities include teaching the courses Pharmaceutical Analysis II and Organic Structure Elucidation.

Dr. Anna Codina

Director Pharmaceutical Business Unit, Bruker BioSpin

Anna has a degree in Chemistry and a PhD in Protein NMR from the University of Barcelona, Spain. During this time she did several industrial placements at pharmaceutical industries (Pharmhispania, Spain, and Genentech, SF, USA) and she worked for the NMR service of the University. She then moved to Cambridge, UK, to do a post-doc in protein NMR at the MRC Laboratory of Molecular Biology.

After her post-doc she worked in the Analytical R&D department of Pfizer, UK, for 8 years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation.

She joined Bruker in 2011 as Material Characterisation Laboratory Manager. Since then her role has evolved. She started looking after the pharmaceutical market in 2015 as Product Portfolio Manager. Anna and team launched several products: InsightMR, InsightXpress and InsighCell for process understanding and monitoring; Fragment Based Screening analysis tools, PotencyMR for potency determination of drugs by qNMR; the minispec Form Check for solid form quantification and NMR Instrument Qualification packages to facilitate compliance. She is now director of the pharmaceutical business Unit at Bruker BioSpin.